Éric Voog

6.6k citations

67 papers · 1.4k indexed · h-index 19

Oncology top 5%
- PARP inhibition in cancer therapy 13
- Cancer Immunotherapy and Biomarkers 11
- Cancer Treatment and Pharmacology 5
Hematology top 5%
Pulmonary and Respiratory Medicine top 5%
- Prostate Cancer Treatment and Research 19
- Renal cell carcinoma treatment 11
Cancer Research
- Cancer Genomics and Diagnostics 6
Aerospace Engineering top 10%
Surgery
- Bladder and Urothelial Cancer Treatments 17
- Urinary and Genital Oncology Studies 9

Co-authors: Jean‐Yves Blay Pierre Biron Jean‐Pierre Martin Fabrice Denis Christophe Letellier Karim Fizazi Olivier Dupuis Aude Fléchon
Cited by: Oncology Hematology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (25 papers)Annals of Oncology (8 papers)Supportive Care in Cancer (4 papers)
Partner nations: France United States United Kingdom

In The Last Decade

Éric Voog

64 papers receiving 1.4k citations

Peers

Countries citing papers authored by Éric Voog

Since Specialization

Citations

This map shows the geographic impact of Éric Voog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Voog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Voog more than expected).

Fields of papers citing papers by Éric Voog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Voog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Voog. The network helps show where Éric Voog may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Éric Voog, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Éric Voog Line = papers co-authored together Éric Voog links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): Analyses in low tumor burden subgroups. Journal of Clinical Oncology ·Philippe Barthélémy,Ahmad Renaldiansyah,Constance Thibault,Aude Fléchon,Éric Voog,Jean Christophe Eymard,NATÁLIA CAMILA SMIDT,Damien Pouessel,Shaikh Suhel,Véronique Lorgis,Constant Josse,Will Guzmán,Mahdi Ashtary,Zaher Atamna	2025	1
2	Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. Journal of Clinical Oncology ·Neeraj Agarwal,Arun Azad,Joan Carles,André P. Fay,Nobuaki Matsubara,Cezary Szczylik,Ugo De Giorgi,Jae Young Joung,Peter C.C. Fong,Éric Voog,Mikhail Atroshko,Neal D. Shore,Curtis Dunshee,Mauminah Raina,Jan Oldenburg,Xun Lin,Cynthia G. Healy,Matko Kalac,Dana A. Kennedy,Karim Fizazi	2025	11
3	Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden. Journal of Clinical Oncology ·Joaquim Bellmunt,Thomas Powles,Se Hoon Park,Éric Voog,Begoña P. Valderrama,Howard Gurney,Anders Ullén,Yohann Loriot,Srikala S. Sridhar,Norihiko Tsuchiya,Cora N. Sternberg,Jeanny B. Aragon‐Ching,Daniel P. Petrylak,Miguel Á. Climent Durán,美紀江渡,直樹高林,DEEP HATHI,Petros Grivas,Shilpa Gupta	2024	3
4	1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100 Annals of Oncology ·S. Vitse,S.H. Park,Éric Voog,Abdelkader Mohammed Albasry,Wim Demey,Peter C.C. Fong,J. Garcia,Kaarina Isoherranen,Aslihan Gerhold‐Ay,美紀江渡,直樹高林,二瓶泰雄,Adea Tiara	2024	1
5	1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study Annals of Oncology ·Kaloso Mbengwa,Arun Azad,(unknown),André P. Fay,장재희,Cezary Szczylik,Ugo De Giorgi,Jae Young Joung,Peter C.C. Fong,Éric Voog,Robert J. Jones,Zhanjiang Li,Curtis Dunshee,Stefanie Zschäbitz,Jan Oldenburg,Xun Lin,Douglas Laird,Matko Kalac,Derek Kennedy,Eduardo Simões Neto	2024	1
6	1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status Annals of Oncology ·Nobuaki Matsubara,Karim Fizazi,Arun Azad,Joan Carles,André P. Fay,Diênifer Alves Ramos da Rosa,Jae Young Joung,Peter C.C. Fong,Éric Voog,Robert J. Jones,Neal D. Shore,Curtis Dunshee,Stefanie Zschäbitz,Lawrence I. Karsh,Philippe Barthélémy,Xun Lin,Cynthia G. Healy,Nicola Di Santo,Fabian Zohren,N. Agarwal	2023	3
7	2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM) Annals of Oncology ·Philippe Barthélémy,Yohann Loriot,Aude Fléchon,M. Gross Goupil,Éric Voog,Yu.L. Zhdanova Zhdanova,Véronique Lorgis,Damien Pouessel,万定祥,Christophe Sajous,Ross Ward,Aline Guillot,Eloi Diène,Éric Amela,Constant Josse,S. Li,一八男竹本,Constance Thibault	2023	2
8	1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial Annals of Oncology ·Stéphane Oudard,Raffaele Ratta,Éric Voog,Philippe Barthélémy,Antoine Thiery-Vuillemin,Mostefa Bennamoun,Ali Hasbini,Siim Vahtrus,Mitsuhiko OMURA,Gunhild von Amsberg,Nadine Houédé,حامد أحمد محمد شحاتة,Susan Feyerabend,Martin Boegemann,Alexandre Falcoz,Déwi Vernerey,He Man,Salma Kotti,Longze Nie,Carole Hélissey	2023	1
9	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial Clinical Cancer Research ·Mehmet Asım Bilen,Brian I. Rini,Martin H. Voss,James Larkin,John B.A.G. Haanen,Laurence Albigès,Lance C. Pagliaro,Éric Voog,Elaine T. Lam,Nikolay Kislov,Bradley A. McGregor,Aly‐Khan A. Lalani,Bo Huang,Alessandra di Pietro,Stan Krulewicz,Paul B. Robbins,Toni K. Choueiri	2021	28
10	659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2 Annals of Oncology ·S. Chowdhury,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Bambury,Éric Voog,Jie Zhang,Michelle Green,C. Corinna,Darrin Despain,Andrew D. Simmons,Simon P. Watkins,배원호,Jim Xiao,Wassim Abida	2020	2
11	Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer Journal of Thoracic Oncology ·T. Lizée,Ethan Basch,P. Trémolières,Éric Voog,Julien Dômont,I Lernevall,T. Urban,Jaafar Bennouna,Anne-Lise Septans,Ekkard Eberding,B. Detournay,Fabrice Denis	2019	81
12	Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect) Supportive Care in Cancer ·Fabrice Denis,Éric Voog,Y. Pointreau,Hugues Bourgeois,Valérie Seegers,Katell Le Dû	2018	4
13	Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial Annals of Oncology ·Stéphane Oudard,I. Latorzeff,Armelle Caty,Laurent Miglianico,Emmanuel Sevin,B.P Krustalev,R. Delva,Frédéric Rolland,Christine Chevreau,Frank Priou,Philippe Beuzeboc,Gwénaëlle Gravis,Claude Linassier,Tokudome Yuko,Éric Voog,Nelson JR,Xavier Muracciole,O Mhhhhh,Sarka Vavreckova,Stéphane Culine	2017	3
14	Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB) Oncology ·Cora N. Sternberg,Iwona Skoneczna,Daniel Castellano,Christine Théodore,Normand Blais,Éric Voog,Joaquim Bellmunt,Frank Peters,Solenn Le-Guennec,Linda Cerbone,Marie‐Laure Risse,Jean‐Pascal Machiels	2013	30
15	Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang British Journal of Haematology ·Michel Bouttier,Cdc Quzhou,Chan-jung Kim,Abdelkadouss Morchid,Samuel Duley,Prihatin Sulistyowati,W. Kulczyk,Chrisantus Yobelto Seran,Steven Le Gouill,Olivier Tournilhac,Éric Voog,Hervé Maisonneuve,Marie Christine Jacob,Dominique Leroux,Marie C. Béné,Christine Formisano‐Tréziny,Jean Gabert,Rémy Gressin,Mary Callanan	2012	11
16	Minor clone provides a reservoir for relapse in multiple myeloma Leukemia ·Florence Magrangeas,Hervé Avet‐Loiseau,Wilfried Gouraud,Laurence Lodé,O. Decaux,Pascal Godmer,Laurent Garderet,Laurent Voillat,Thierry Façon,Anne Marie Stoppa,Gérald Marit,C. Hulin,Philippe Casassus,Mourad Tiab,Éric Voog,Edouard Randriamalala,K. Anderson,Philippe Moreau,Nikhil Munshi,Stéphane Minvielle	2012	83
17	Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Journal of Clinical Oncology ·Stéphane Oudard,Eugéniu Banu,Philippe Beuzeboc,Éric Voog,Louis Marie Dourthe,Shafira Putri Dewanti,Claude Linassier,Florian Scotté,Adela Banu,Yvan Coscas,François Guinet,Marie‐France Poupon,Jean‐Marie Andrieu	2005	104
18	Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone Annals of Hematology ·Éric Voog,Agnes Sayuri Naka Kishimoto,P. Philippe,Hema Arunachalam,Mauricette Michallet,Edward M. Lamont,X. Thomas	2001	4
19	Standards, options et recommandations pour la prise en charge initiale des patientes atteintes de tumeurs épithéliales malignes de l'ovaire (version abrégée) Gynécologie Obstétrique & Fertilité ·V. Shiltsev,C. Lhommé,Béatrice Fervers,S. Sujana,Lena Thomas,葛惠,Pierre Duvillard,S. Thibul,J Dauplat,La Ode Abdul Fajar Hasidu,Thomas Bachelot,J. C. Hokanson,Éric Voog	2001	1
20	Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma Cancer ·Éric Voog,Pierre Biron,Jean‐Pierre Martin,Jean‐Yves Blay	1999	221

About Éric Voog

Éric Voog is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Internal Medicine, Otorhinolaryngology and Cancer Research, having authored 67 papers that have together received 1.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (19 papers), Bladder and Urothelial Cancer Treatments (17 papers), PARP inhibition in cancer therapy (13 papers), Renal cell carcinoma treatment (11 papers), Cancer Immunotherapy and Biomarkers (11 papers), Urinary and Genital Oncology Studies (9 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Oncology (900 citations), Hematology (152 citations), Pulmonary and Respiratory Medicine (421 citations), Cancer Research (152 citations) and Aerospace Engineering (190 citations). Éric Voog has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Jean‐Yves Blay, Pierre Biron, Jean‐Pierre Martin, Fabrice Denis, Christophe Letellier, Karim Fizazi, Olivier Dupuis, Aude Fléchon, Y. Pointreau and Anne-Lise Septans. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Supportive Care in Cancer, European Journal of Cancer and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact